How NeuroScientific’s $1.7M Loss Fuels Breakthroughs in Crohn’s and Glaucoma Treatments

Financial Performance and R&D Focus

NeuroScientific Biopharmaceuticals Limited (ASX: NSB) has released its interim results for the half-year ended 31 December 2025, reporting a net loss of $1.7 million. This represents a significant increase compared to the $367,554 loss recorded in the same period last year, primarily reflecting intensified research and development activities and corporate overheads.

The company’s cash position remains robust, with a working capital surplus of approximately $6.36 million, including cash and term deposits. This financial buffer supports ongoing clinical and pre-clinical programs, underpinning the company’s strategic focus on neurodegenerative and immune-mediated inflammatory diseases.

Clinical Progress and Regulatory Engagement

During the period, NeuroScientific advanced its clinical pipeline notably through the acquisition and development of StemSmart™, a mesenchymal stem cell therapy targeting fistulising Crohn’s disease. Leveraging the Therapeutic Goods Administration’s Special Access Scheme, the company treated four patients by year-end, with promising clinical outcomes reported for three patients in early 2026.

Simultaneously, the pre-clinical development of EmtinB, aimed at treating degenerative conditions such as glaucoma, progressed with a focus on developing an intravitreal formulation suitable for ocular administration. Collaborations with pharmaceutical development specialists Quotient Sciences and testing provider Eurofins CALIXAR align this program with FDA pre-Investigational New Drug guidance, positioning it for future regulatory milestones.

Leadership and Strategic Partnerships

In July 2025, NeuroScientific strengthened its executive team by appointing Nathan Smith as CEO and Dr Catherine Cole as Chief Medical Officer. Both bring extensive expertise in manufacturing, clinical development, and corporate leadership, expected to accelerate the company’s development trajectory.

Further, the company entered a key partnership with Q-Gen Cell Therapeutics, a leading Australian cell therapy contract manufacturer, to facilitate the technology transfer of StemSmart™ manufacturing processes. This collaboration is critical for scaling clinical trials and exploring commercial opportunities.

Outlook and Governance

No dividends were declared for the half-year, consistent with the company’s focus on reinvesting in its pipeline. The interim financial report was reviewed by Nexia Perth Audit Services with no qualifications, affirming the integrity of the disclosures. Directors remain confident in the company’s going concern status, supported by cash reserves and the ability to manage costs and raise funds if necessary.

Looking ahead, NeuroScientific’s progress with StemSmart™ under the Special Access Scheme and the advancement of EmtinB’s formulation development will be key value drivers. Investors will be watching closely for further clinical data, regulatory updates, and potential partnerships that could unlock commercial value.